血管性痴呆患者认知功能障碍采用舒血宁与吡拉西坦 治疗对其MMSE及ADL评分的影响

庞啸虎，吴秀玮，许庆，高丽

（徐州市第一人民医院神经内科，江苏 徐州，221002）

浏览次数：67次 下载次数：300次

摘要：

目的 探讨血管性痴呆患者认知功能障碍采用舒血宁与吡拉西坦治疗对其MMSE 及ADL 评分的影响。方法 将2016年 2月至2017 年2 月在我院精神病科治疗的104 例血管性痴呆伴有认知功能障碍患者随机分为对照组和观察组，各52 例。对照 组患者单用吡拉西坦治疗，观察组采用舒血宁联合吡拉西坦治疗。对比分析两组患者的临床疗效、治疗前、后的症状变化及生 活能力改善情况。结果 观察组患者的治疗总有效率为94.23%，明显高于对照组的75.00%（P<0.05）。治疗后，两组患者定向力、回忆能力、语言能力、MMSE 总分评分均升高，且观察组均明显高于对照组（P<0.05）。治疗后，两组患者的躯体生活自理能力、使 用工具能力及ADL总分评分均明显降低，且观察组明显低于对照组（P<0.05）。结论 血管性痴呆患者认知功能障碍采用舒血宁 与吡拉西坦治疗效果显著，能明显改变痴呆及认知功能障碍的症状，延缓患者的脑部功能衰退，改进日常生活的能力。

关键词：血管性痴呆；认知功能障碍；舒血宁；吡拉西坦

中图分类号：R749.1文献标志码：A文章编号：2096-1413(2017)35-0032-02

Effect of Shuxuening and piracetam on cognitive impairment in patients with vascular dementia and its

influence on MMSE and ADL score
PANG Xiao-hu, WU Xiu-wei, XU Qing, Gao Li
(Neurology Department, the First People``s Hospital of Xuzhou, Xuzhou 221002, China)

ABSTRACT: Objective To study the effect of Shuxuening and piracetam on cognitive impairment in patients with vascular dementia and its influence on MMSE and ADL scores. Methods From February 2016 to February 2017, 104 cases of vascular dementia patients with cognitive impairment in our hospital were randomly divided into control group and observation group, with 52 cases in each group. Patients in the control group were treated with piracetam alone, while patients in the observation group received Shuxuening combined with piracetam. The clinical efficacy, changes of symptoms, improvement of living ability before and after treatment were compared between the two groups. Results The total effective rate of the observation group was 94.23%, which was significantly higher than 75.00% of the control group (P<0.05). After treatment, the scores of orientation ability, recall ability, language ability and total MMSE score of the two groups increased, and those of the observation group were higher than the control group (P<0.05). After treatment, the scores of physical activity self-care ability, using tools and total ADL score of the two groups decreased, and those of the observation group were lower than the control group (P<0.05). Conclusion In the treatment of cognitive dysfunction in patients with vascular dementia, Shuxuening combined with Piracetam can effectively improve the symptoms of dementia and cognitive dysfunction, delay the decline of brain function, and promote the improvement of daily living ability.

KEYWORDS: vascular dementia; cognitive impairment; Shuxuening; piracetam

参考文献：
[1] 胡宁,楼敏芳,姜纪敏.舒血宁联合吡拉西坦对血管性痴呆患者认 知功能障碍的影响[J].海峡药学,2012,24(11):109-110.
[2] 中华医学会神经病学分会.血管性痴呆诊断标准草案[J].中华神经 科杂志,2002,35(4):246.
[3] 李富慧.舒血宁注射液联合吡拉西坦治疗血管性痴呆的疗效[J].中 国老年学杂志,2011,31(12):2315-2316.
[4] 陈文明.舒血宁联合吡拉西坦在老年血管性痴呆治疗中的应用效 果[J].中国医学工程,2016,24(6):98-99.
[5] 陈爱华.吡拉西坦片联合丁苯酞软胶囊治疗血管性痴呆的临床疗 效观察[J].实用中西医结合临床,2016,16(2):22-23.
[6] 马文娟.舒血宁联合脑复康治疗血管性痴呆的疗效及对认知功能 障碍的影响[J].现代预防医学,2012,39(2):458-459.